Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Eton Pharmaceuticals, Inc. (ETON)
Last eton pharmaceuticals, inc. earnings: 3/5 04:02 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS of $0.19, and Adjusted EBITDA of $6.2 million Launched DESMODA™, the first and only FDA-approved desmopressin oral solution Licensed U.S. rights to Orphan Drug HEMANGEOL ® ; expected to be accretive to 2026 earnings Company expects full year 2026 revenue to exceed $110 million with an Adjusted EBITDA margin of over 30% Management to hold conference call today at 4:30pm ET DEER PARK, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended December 31, 2025. “It was another phenomenal quarter for Eton with meaningful contributions from key products across our portfolio including INCRELEX, ALKINDI SPRINKLE, KHINDIVI, and GALZIN. The strong fo
Show less
Read more
Impact Snapshot
Event Time:
ETON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ETON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ETON alerts
High impacting Eton Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ETON
News
- Eton Pharmaceuticals (ETON) was upgraded by Zacks Research from "hold" to "strong-buy".MarketBeat
- Eton Pharmaceuticals (ETON) had its price target raised by HC Wainwright from $37.00 to $52.00. They now have a "buy" rating on the stock.MarketBeat
- Eton Pharmaceuticals (ETON) had its price target raised by B. Riley Financial, Inc. from $26.00 to $31.00. They now have a "buy" rating on the stock.MarketBeat
- Eton Pharmaceuticals (ETON) had its price target raised by Craig Hallum from $30.00 to $35.00. They now have a "buy" rating on the stock.MarketBeat
- Eton Pharmaceuticals Inc (ETON) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
ETON
Earnings
- 3/19/26 - Beat
ETON
Sec Filings
- 3/19/26 - Form 8-K
- 3/19/26 - Form 10-K
- 3/6/26 - Form S-8
- ETON's page on the SEC website